Advertisement

Topics

MorphoSys posts positive data for lymphoma drug, but will it compete with CAR-Ts?

11:12 EDT 17 May 2019 | MedCity News

A spokesperson for the company noted that patients in the Phase II L-MIND trial of the CD19-targeting drug tafasitamab would be too old and frail to be candidates for CAR-T therapies.

Original Article: MorphoSys posts positive data for lymphoma drug, but will it compete with CAR-Ts?

NEXT ARTICLE

More From BioPortfolio on "MorphoSys posts positive data for lymphoma drug, but will it compete with CAR-Ts?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...